Ronald G Hall

Summary

Affiliation: Texas Tech University Health Sciences Center
Country: USA

Publications

  1. pmc Multicenter evaluation of vancomycin dosing: emphasis on obesity
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
    Am J Med 121:515-8. 2008
  2. pmc Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, TX, USA
    BMC Pharmacol Toxicol 14:12. 2013
  3. pmc Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, TX, USA
    BMC Infect Dis 12:104. 2012
  4. pmc Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
    Antimicrob Agents Chemother 56:1502-7. 2012
  5. pmc A formalized teaching, practice, and research partnership with the Veterans Affairs North Texas Health Care System: a model for advancing academic partnerships
    Ronald G Hall
    Texas Tech University Health Sciences Center, TX, USA
    Am J Pharm Educ 73:141. 2009
  6. pmc Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, Dallas, Texas 75235, USA
    Pharmacotherapy 29:1468-81. 2009
  7. ncbi request reprint Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin
    Anthony J Busti
    School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75216, USA
    J Cardiovasc Pharmacol 51:605-10. 2008
  8. doi request reprint Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind
    Amy Arnold
    Texas Tech University Health Sciences Center, Dallas, TX 75235, USA
    J Intensive Care Med 25:259-70. 2010
  9. pmc Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
    Antimicrob Agents Chemother 57:2259-64. 2013
  10. pmc Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?
    Kathleen A Hazlewood
    Texas Tech University Health Sciences Center, Dallas, TX, USA
    Am J Med 123:182.e1-7. 2010

Collaborators

Detail Information

Publications19

  1. pmc Multicenter evaluation of vancomycin dosing: emphasis on obesity
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
    Am J Med 121:515-8. 2008
    ..There is a paucity of data available regarding the dosing of antimicrobials in obesity. However, data are available demonstrating that vancomycin should be dosed on the basis of actual body weight...
  2. pmc Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, TX, USA
    BMC Pharmacol Toxicol 14:12. 2013
    ..However, data are currently lacking regarding the effect of guideline-recommended weight-based dosing on nephrotoxicity in methicillin-resistant Staphylococcus aureus bacteremia (MRSAB)...
  3. pmc Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, TX, USA
    BMC Infect Dis 12:104. 2012
    ..No studies have evaluated the effect of guideline-recommended weight-based dosing on in-hospital mortality of patients with methicillin-resistant Staphylococcus aureus bacteremia...
  4. pmc Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
    Antimicrob Agents Chemother 56:1502-7. 2012
    ..On the other hand, such reduced AUCs could lead to therapy failure. Thus, new and individualized ethambutol dosing regimens need to be designed for obese and extremely obese patients...
  5. pmc A formalized teaching, practice, and research partnership with the Veterans Affairs North Texas Health Care System: a model for advancing academic partnerships
    Ronald G Hall
    Texas Tech University Health Sciences Center, TX, USA
    Am J Pharm Educ 73:141. 2009
    ..The VANTHCS/pharmacy school collaboration has clearly enhanced the ability of both institutions to exceed their teaching, research, and practice goals in a cost-effective manner...
  6. pmc Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, Dallas, Texas 75235, USA
    Pharmacotherapy 29:1468-81. 2009
    ..These patient factors, the covariates for pharmacokinetic variability, and PK-PD factors suggest the need to individualize therapy for patients with tuberculosis in order to optimize outcomes and reduce the duration of therapy...
  7. ncbi request reprint Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin
    Anthony J Busti
    School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75216, USA
    J Cardiovasc Pharmacol 51:605-10. 2008
    ..The objective is to study the pharmacokinetic interaction of RSV with atazanavir/ritonavir (ATV/RTV) or fosamprenavir/ritonavir (FPV/RTV)...
  8. doi request reprint Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind
    Amy Arnold
    Texas Tech University Health Sciences Center, Dallas, TX 75235, USA
    J Intensive Care Med 25:259-70. 2010
    ..Optimizing the use of current antimicrobials is paramount to ensure quality treatment options are available, given the lack of gram-negative antimicrobials in the pipeline...
  9. pmc Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths
    Ronald G Hall
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
    Antimicrob Agents Chemother 57:2259-64. 2013
    ..This study protocol was registered at www.clinicaltrials.gov under registration number NCT01062165.)...
  10. pmc Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?
    Kathleen A Hazlewood
    Texas Tech University Health Sciences Center, Dallas, TX, USA
    Am J Med 123:182.e1-7. 2010
    ..aureus isolates...
  11. doi request reprint Therapy duration and long-term outcomes in extra-pulmonary tuberculosis
    Tobias Pusch
    Department of Medicine, University of Texas Southwestern Medical Center, Dallas, USA
    BMC Infect Dis 14:115. 2014
    ..While much focus has been paid to pulmonary tuberculosis, EPTB has received scant attention. Moreover, EPTB is viewed as one wastebasket diagnosis, as "the other" which is not pulmonary...
  12. ncbi request reprint Dosing of antibacterial agents in obese adults: does one size fit all?
    Kenna D Payne
    Texas Tech University Health Sciences Center, 1300 S Coulter, Rm 323, Amarillo, TX 79106, USA
    Expert Rev Anti Infect Ther 12:829-54. 2014
    ..Yet other antimicrobials are reported to need no dose adjustment, largely based on studies using body mass index groups. Therefore, each drug should be individually evaluated to determine the proper dose for obese persons. ..
  13. ncbi request reprint Atazanavir for the treatment of human immunodeficiency virus infection
    Anthony J Busti
    Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, Texas, USA
    Pharmacotherapy 24:1732-47. 2004
    ..We conclude that atazanavir is a distinctively characteristic protease inhibitor owing to its in vitro potency, once-daily dosing, distinct initial resistance pattern, and infrequent association with metabolic abnormalities...
  14. ncbi request reprint In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae
    David S Burgess
    College of Pharmacy, University of Texas at Austin, Austin, TX, USA
    Diagn Microbiol Infect Dis 49:41-6. 2004
    ..pneumoniae, their activity against ESBL K. pneumoniae is limited and based on the size of the inoculum. Until more data are available, piperacillin/tazobactam and cefepime should not be used for the treatment of ESBL K. pneumoniae...
  15. ncbi request reprint In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa
    David S Burgess
    College of Pharmacy, The University of Texas at Austin, Austin, TX, USA
    Diagn Microbiol Infect Dis 46:131-7. 2003
    ..aeruginosa may prove to be clinically beneficial and superior to combinations using lower doses of levofloxacin. In vivo studies are needed to evaluate the clinical significance of these findings...
  16. ncbi request reprint Vancomycin dosing for methicillin-resistant staphylococcus aureus nosocomial pneumonia
    Ronald G Hall
    Chest 132:1100-1; author reply 1102-3. 2007
  17. ncbi request reprint Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data
    David S Burgess
    Center for Advancement of Research and Education in Infectious Diseases, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78229, USA
    Clin Ther 29:1421-7. 2007
    ..Until the 2002 approval of levofloxacin 750 mg QD, ciprofloxacin was the fluoroquinolone of choice against Pseudomonas aeruginosa infections...
  18. ncbi request reprint Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus
    Darego O Maclayton
    Texas Southern University College of Pharmacy and Health Sciences, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX 77004, USA
    Ann Pharmacother 41:235-44. 2007
    ..To discuss current and potential treatment options for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA)...
  19. ncbi request reprint Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period
    David S Burgess
    College of Pharmacy, University of Texas at Austin, USA
    Pharmacotherapy 23:1232-7. 2003
    ..To evaluate the microbiologic and clinical outcomes of patients with extended-spectrum beta-lactamase (ESBL)-producing isolates over a 2-year period...